Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .
The effects of soy isoflavone on bone density in north region of climacteric Chinese women
Only a few investigations were based on limb bone density . This study evaluated the efficacy of soy isoflavone in the treatment of the principal menopausal disorders , limb bone density and the role of pathway . The research protocol involved the r and om subdivision of the enrolled sample into two groups of 40 women , who were to receive treatment for 6 months with isoflavone ( 90 mg/day ) and with placebo .  All of the patients were asked to fill in a question naire concerning their complaints . BMD of the radius and tibia were measured using quantitative ultrasound . Bone metabolism indexes calcium , phosphorus and alkaline phosphatase ( ALP ) were examined regularly . Serum cytokines interleukin-6 ( IL-6 ) and tumor necrosis factor-α ( TNF-α ) examined by ELISA . The results of the score of Kupperman table showed that the isoflavone can lead to a significant reduction in some of the disorders . Compared with placebo , the tibia bone density in isoflavone group increased obviously against the base value before trail . Isoflavone led to a stronger descent of the concentration of ALP and a decrease of IL-6 and TNF-α level than placebo . For climacteric women  , soy isoflavone in the dose of 90 mg/day could improve some menopausal syndromes and was effective on increasing limb bone density , which maybe had the relationship with the levels of IL-6 , TNF-α and ALP in serum
Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .